IBOV 172,060.43 ▲ 0.42% IPC MEX 72,006.05 ▲ 0.16% MERVAL 2,848,945 — — USD/BRL5.58▼ 0.04% USD/MXN18.58▼ 0.12% USD/CLP982.08▼ 0.22% USD/COP3,279▼ 0.85% USD/PEN3.41▼ 0.02% USD/ARS1,544▼ 0.03% USD/UYU40.52▲ 3.70% USD/PYG6,174▲ 3.14% USD/BOB11.63▲ 1.12% USD/DOP60.48▲ 0.05% USD/CRC446.01▲ 1.79% USD/GTQ7.64▲ 3.16% USD/HNL26.90▲ 3.29% USD/NIO36.62▲ 2.73% USD/VES902.19▲ 0.19% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.49▲ 2.41% USD/TTD6.72▲ 2.22% EUR/BRL6.19▼ 0.68% BRENT 93.60 ▲ 0.91% WTI 87.29 ▲ 0.88% IRON ORE 161.91 — — COPPER 6.24 ▼ 0.53% GOLD 3,954 ▼ 1.15% SILVER 51.30 ▼ 1.13% SOY 1,226 ▼ 0.28% CORN 447.00 ▼ 0.22% WHEAT 599.50 — 0.00% COFFEE 265.45 ▼ 2.19% SUGAR 18.47 ▲ 2.10% ORANGE JUICE 146.60 ▼ 0.10% COTTON 82.35 ▲ 4.65% COCOA 5,061 ▲ 6.73% BEEF 218.98 ▼ 0.10% CATTLE 327.80 ▼ 0.77% LITHIUM 61.07 ▲ 1.82% PETR4 43.55 ▼ 3.11% VALE3 64.43 ▼ 0.57% ITUB4 41.72 ▲ 1.26% BBDC4 14.33 ▼ 1.44% ABEV3 15.85 ▲ 0.38% BBAS3 16.89 ▼ 1.23% B3SA3 14.80 ▲ 2.21% WEGE3 51.61 ▲ 1.30% PRIO3 61.47 ▲ 2.42% SUZB3 53.80 ▼ 1.21% RENT3 30.24 ▲ 1.51% AZZA3 15.37 ▲ 4.34% CSAN3 3.03 ▲ 13.06% RAIZ4 0.30 ▼ 98.60% PCAR3 2.54 ▼ 0.78% GMAT3 4.08 ▲ 7.09% PSSA3 45.98 ▼ 1.48% CVCB3 0.86 — 0.00% POSI3 3.32 ▲ 5.40% SLCE3 17.05 ▼ 0.23% NATU3 5.62 ▲ 1.26% BRKM5 2.92 — 0.00% RANI3 8.39 ▼ 0.71% CSNA3 4.52 ▲ 3.20% IBOV 172,060.43 ▲ 0.42% IPC MEX 72,006.05 ▲ 0.16% MERVAL 2,848,945 — — USD/BRL 5.58 ▼ 0.04% USD/MXN 18.58 ▼ 0.12% USD/CLP 982.08 ▼ 0.22% USD/COP 3,279 ▼ 0.85% USD/PEN 3.41 ▼ 0.02% USD/ARS 1,544 ▼ 0.03% USD/UYU 40.52 ▲ 3.32% USD/PYG 6,174 ▲ 3.14% USD/BOB 11.63 ▲ 1.12% USD/DOP 60.48 ▲ 0.13% USD/CRC 446.01 ▲ 1.79% USD/GTQ 7.64 ▲ 3.16% USD/HNL 26.90 ▲ 3.29% USD/NIO 36.62 ▲ 2.73% USD/VES 902.19 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.49 ▲ 2.41% USD/TTD 6.72 ▲ 2.22% EUR/BRL 6.19 ▼ 0.67% BRENT 93.60 ▲ 0.91% WTI 87.29 ▲ 0.88% IRON ORE 161.91 — — COPPER 6.24 ▼ 0.53% GOLD 3,954 ▼ 1.15% SILVER 51.30 ▼ 1.13% SOY 1,226 ▼ 0.28% CORN 447.00 ▼ 0.22% WHEAT 599.50 — 0.00% COFFEE 265.45 ▼ 2.19% SUGAR 18.47 ▲ 2.10% ORANGE JUICE 146.60 ▼ 0.10% COTTON 82.35 ▲ 4.65% COCOA 5,061 ▲ 6.73% BEEF 218.98 ▼ 0.10% CATTLE 327.80 ▼ 0.77% LITHIUM 61.07 ▲ 1.82% PETR4 43.55 ▼ 3.11% VALE3 64.43 ▼ 0.57% ITUB4 41.72 ▲ 1.26% BBDC4 14.33 ▼ 1.44% ABEV3 15.85 ▲ 0.38% BBAS3 16.89 ▼ 1.23% B3SA3 14.80 ▲ 2.21% WEGE3 51.61 ▲ 1.30% PRIO3 61.47 ▲ 2.42% SUZB3 53.80 ▼ 1.21% RENT3 30.24 ▲ 1.51% AZZA3 15.37 ▲ 4.34% CSAN3 3.03 ▲ 13.06% RAIZ4 0.30 ▼ 98.60% PCAR3 2.54 ▼ 0.78% GMAT3 4.08 ▲ 7.09% PSSA3 45.98 ▼ 1.48% CVCB3 0.86 — 0.00% POSI3 3.32 ▲ 5.40% SLCE3 17.05 ▼ 0.23% NATU3 5.62 ▲ 1.26% BRKM5 2.92 — 0.00% RANI3 8.39 ▼ 0.71% CSNA3 4.52 ▲ 3.20%
since 2009
Thursday, November 12, 2026

Latin America Brazil

Promising Research to Combat SARS-Cov-2 Virus Being Conducted in Cuba

By · · 3 min read

RIO DE JANEIRO, BRAZIL – The employees of the Cuban Biotechnology and Pharmaceutical Industry Group (Biocubafarma) are currently working intensively in the fight against the coronavirus pandemic and are developing research in various directions.

The Biocubafarma is currently working on 15 projects to prevent and fight Covid-19, the disease caused by the novel coronavirus SARS-Cov-2.
The Biocubafarma is currently working on 15 projects to prevent and fight Covid-19, the disease caused by the novel coronavirus SARS-Cov-2.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

They are focusing on the development of drugs to boost the immune systems of high-risk individuals, on drugs with antiviral effects, and on drugs to prevent the death of seriously or critically ill patients.

The Biocubafarma is currently working on 15 projects to prevent and fight Covid-19, the disease caused by the novel coronavirus SARS-Cov-2.

Dr. Eduardo Martinez, President of the state-owned Biocubafarma said that in recent weeks two drugs that boost the immune system have been included in the protocol for the fight against the Covid-19 pulmonary disease: Biomodulin and a transfer factor.

In addition, a variant of interferon is being produced for nasal application, which is to be used preventively for the same purpose. In parallel, two broad-spectrum vaccines are already being tested to boost the immune system of people susceptible to viral infections.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Petrobras to pay shareholders US$2.7 billion”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Rita María García, the company’s Director of Operations and Technology, said that the company has prepared itself to ensure sufficient raw materials, stocks and spare components to produce the quantities required in the current epidemiological crisis.

This must be achieved despite the restrictions imposed by the US blockade against Cuba. The antiviral recombinant interferon alpha 2B is a leading product of Cuban biotechnology.

It is manufactured in China at the Center for Genetic Engineering and Biotechnology (CIGB) and the Cuban-Chinese joint venture ChangHeber, where it is administered as a preventive measure to vulnerable health workers and Covid-19 patients.

Six clinical trials are currently underway in Cuba for the treatment of Covid-19 patients, six for prophylactic use in separate risk groups, two diagnostic kits and medical devices (artificial respirators), said Rolando Perez, Director of Science and Research at Biocubafarma. He explained that the body’s own defenses are the “first line of defense” against infection and that the immune system plays a key role in the course of the disease.

Consequently, most of the products the Cuban specialists are working on aim to strengthen it in order to reduce complications and the severity of the disease process and to prevent deaths.

The aforementioned drug Biomodulin has been shown to be effective in patients by preventing Covid-19 from progressing to severe stages, said Gerardo Guillen, director of biomedical research at the CIGB. The drug will be particularly beneficial for vulnerable groups such as people over 60 years of age, the chronically ill or people with weakened immune systems.

This is very significant as it is the first time that a pandemic is controlled through the adoption of isolation measures and a large part of the population is susceptible to the virus but is not exposed to it.

Therefore, even after the current crisis is over, new cases of infections may occur.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.